<?xml version="1.0" encoding="UTF-8"?>
<!-- Version: 1.1.1121.0 -->
<!-- Document created: 02-05-2022 11:50:30 -->
<!-- Created by:  XBRL Wizard, EasyX -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://xbrl.org/2006/xbrldi http://www.xbrl.org/2006/xbrldi-2006.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:entry="http://xbrl.dcca.dk/entryBalanceSheetAccountFormIncomeStatementByFunction" xmlns:arr="http://xbrl.dcca.dk/arr" xmlns:gen="http://xbrl.org/2008/generic" xmlns:tch="http://xbrl.dcca.dk/tch" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:label="http://xbrl.org/2008/label" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:cmn="http://xbrl.dcca.dk/cmn" xmlns:gsd="http://xbrl.dcca.dk/gsd" xmlns:tax="http://xbrl.dcca.dk/tax" xmlns:variable="http://xbrl.org/2008/variable" xmlns:eogs="http://xbrl.dcca.dk/eogs" xmlns:dst="http://xbrl.dcca.dk/dst" xmlns:valm="http://xbrl.org/2010/message/validation" xmlns:msg="http://xbrl.org/2010/message" xmlns:fsa="http://xbrl.dcca.dk/fsa" xmlns:mrv="http://xbrl.dcca.dk/mrv" xmlns:esg="http://xbrl.dcca.dk/esg" xmlns:sob="http://xbrl.dcca.dk/sob" xmlns:tar="http://xbrl.dcca.dk/tar">
  <link:schemaRef xlink:type="simple" xlink:href="http://archprod.service.eogs.dk/taxonomy/20211001/entryDanishGAAPBalanceSheetAccountFormIncomeStatementByFunctionIncludingManagementsReviewStatisticsAndTax20211001.xsd" />
  <xbrli:context id="ctx1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="ctx2">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfExecutiveBoardDimension">
        <cmn:memberOfBoardIdentifier>0</cmn:memberOfBoardIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx3">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
        <cmn:memberOfBoardIdentifier>0</cmn:memberOfBoardIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx4">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
        <cmn:memberOfBoardIdentifier>1</cmn:memberOfBoardIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx5">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
        <cmn:memberOfBoardIdentifier>2</cmn:memberOfBoardIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx6">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:PreviousYearMember</xbrldi:explicitMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx7">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:TwoYearsAgoMember</xbrldi:explicitMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx8">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:ThreeYearsAgoMember</xbrldi:explicitMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx9">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:FourYearsAgoMember</xbrldi:explicitMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx10">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
        <mrv:keyFigureOrFinancialRatioIdentifier>0</mrv:keyFigureOrFinancialRatioIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx11">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:PreviousYearMember</xbrldi:explicitMember>
      <xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
        <mrv:keyFigureOrFinancialRatioIdentifier>1</mrv:keyFigureOrFinancialRatioIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx12">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:TwoYearsAgoMember</xbrldi:explicitMember>
      <xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
        <mrv:keyFigureOrFinancialRatioIdentifier>2</mrv:keyFigureOrFinancialRatioIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx13">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:ThreeYearsAgoMember</xbrldi:explicitMember>
      <xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
        <mrv:keyFigureOrFinancialRatioIdentifier>3</mrv:keyFigureOrFinancialRatioIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx14">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:FourYearsAgoMember</xbrldi:explicitMember>
      <xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
        <mrv:keyFigureOrFinancialRatioIdentifier>4</mrv:keyFigureOrFinancialRatioIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx15">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
        <mrv:keyFigureOrFinancialRatioIdentifier>5</mrv:keyFigureOrFinancialRatioIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx16">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:PreviousYearMember</xbrldi:explicitMember>
      <xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
        <mrv:keyFigureOrFinancialRatioIdentifier>6</mrv:keyFigureOrFinancialRatioIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx17">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:TwoYearsAgoMember</xbrldi:explicitMember>
      <xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
        <mrv:keyFigureOrFinancialRatioIdentifier>7</mrv:keyFigureOrFinancialRatioIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx18">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:ThreeYearsAgoMember</xbrldi:explicitMember>
      <xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
        <mrv:keyFigureOrFinancialRatioIdentifier>8</mrv:keyFigureOrFinancialRatioIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx19">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:FourYearsAgoMember</xbrldi:explicitMember>
      <xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
        <mrv:keyFigureOrFinancialRatioIdentifier>9</mrv:keyFigureOrFinancialRatioIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx20">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="ctx21">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-11-30</xbrli:instant>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:PreviousYearMember</xbrldi:explicitMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx22">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-11-30</xbrli:instant>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:TwoYearsAgoMember</xbrldi:explicitMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx23">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-11-30</xbrli:instant>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:ThreeYearsAgoMember</xbrldi:explicitMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx24">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-11-30</xbrli:instant>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:FourYearsAgoMember</xbrldi:explicitMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx25">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
        <mrv:keyFigureOrFinancialRatioIdentifier>10</mrv:keyFigureOrFinancialRatioIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx26">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:PreviousYearMember</xbrldi:explicitMember>
      <xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
        <mrv:keyFigureOrFinancialRatioIdentifier>11</mrv:keyFigureOrFinancialRatioIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx27">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:TwoYearsAgoMember</xbrldi:explicitMember>
      <xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
        <mrv:keyFigureOrFinancialRatioIdentifier>12</mrv:keyFigureOrFinancialRatioIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx28">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:ThreeYearsAgoMember</xbrldi:explicitMember>
      <xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
        <mrv:keyFigureOrFinancialRatioIdentifier>13</mrv:keyFigureOrFinancialRatioIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx29">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:FourYearsAgoMember</xbrldi:explicitMember>
      <xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
        <mrv:keyFigureOrFinancialRatioIdentifier>14</mrv:keyFigureOrFinancialRatioIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
        <mrv:keyFigureOrFinancialRatioIdentifier>15</mrv:keyFigureOrFinancialRatioIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:PreviousYearMember</xbrldi:explicitMember>
      <xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
        <mrv:keyFigureOrFinancialRatioIdentifier>16</mrv:keyFigureOrFinancialRatioIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx32">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:TwoYearsAgoMember</xbrldi:explicitMember>
      <xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
        <mrv:keyFigureOrFinancialRatioIdentifier>17</mrv:keyFigureOrFinancialRatioIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx33">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:ThreeYearsAgoMember</xbrldi:explicitMember>
      <xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
        <mrv:keyFigureOrFinancialRatioIdentifier>18</mrv:keyFigureOrFinancialRatioIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx34">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:FourYearsAgoMember</xbrldi:explicitMember>
      <xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
        <mrv:keyFigureOrFinancialRatioIdentifier>19</mrv:keyFigureOrFinancialRatioIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx35">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
        <mrv:keyFigureOrFinancialRatioIdentifier>20</mrv:keyFigureOrFinancialRatioIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx36">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:PreviousYearMember</xbrldi:explicitMember>
      <xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
        <mrv:keyFigureOrFinancialRatioIdentifier>21</mrv:keyFigureOrFinancialRatioIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx37">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:TwoYearsAgoMember</xbrldi:explicitMember>
      <xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
        <mrv:keyFigureOrFinancialRatioIdentifier>22</mrv:keyFigureOrFinancialRatioIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx38">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:ThreeYearsAgoMember</xbrldi:explicitMember>
      <xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
        <mrv:keyFigureOrFinancialRatioIdentifier>23</mrv:keyFigureOrFinancialRatioIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx39">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:FourYearsAgoMember</xbrldi:explicitMember>
      <xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
        <mrv:keyFigureOrFinancialRatioIdentifier>24</mrv:keyFigureOrFinancialRatioIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx40">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
        <mrv:keyFigureOrFinancialRatioIdentifier>25</mrv:keyFigureOrFinancialRatioIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx41">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:PreviousYearMember</xbrldi:explicitMember>
      <xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
        <mrv:keyFigureOrFinancialRatioIdentifier>26</mrv:keyFigureOrFinancialRatioIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx42">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:TwoYearsAgoMember</xbrldi:explicitMember>
      <xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
        <mrv:keyFigureOrFinancialRatioIdentifier>27</mrv:keyFigureOrFinancialRatioIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx43">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:ThreeYearsAgoMember</xbrldi:explicitMember>
      <xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
        <mrv:keyFigureOrFinancialRatioIdentifier>28</mrv:keyFigureOrFinancialRatioIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx44">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="cmn:RetrospectiveInformationDimension">cmn:FourYearsAgoMember</xbrldi:explicitMember>
      <xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
        <mrv:keyFigureOrFinancialRatioIdentifier>29</mrv:keyFigureOrFinancialRatioIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx45">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-12-01</xbrli:startDate>
      <xbrli:endDate>2020-11-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="ctx46">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="ctx47">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="fsa:ResultDistributionDimension">fsa:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx48">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-12-01</xbrli:startDate>
      <xbrli:endDate>2020-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="fsa:ResultDistributionDimension">fsa:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx49">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">66351912</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2021-11-30</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:typedMember dimension="cmn:IdentificationOfAuditorDimension">
        <cmn:auditorIdentifier>0</cmn:auditorIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:unit id="vDKK">
    <xbrli:measure>iso4217:DKK</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <fsa:ClassOfReportingEntity contextRef="ctx1">Regnskabsklasse C, stor virksomhed</fsa:ClassOfReportingEntity>
  <gsd:NameOfReportingEntity contextRef="ctx1" xml:lang="da">Pfizer ApS</gsd:NameOfReportingEntity>
  <gsd:IdentificationNumberCvrOfReportingEntity contextRef="ctx1">66351912</gsd:IdentificationNumberCvrOfReportingEntity>
  <gsd:TelephoneNumberOfReportingEntity contextRef="ctx1" xml:lang="da">+45 44 20 11 00</gsd:TelephoneNumberOfReportingEntity>
  <gsd:FaxNumberOfReportingEntity contextRef="ctx1" xml:lang="da">+45 44 20 11 01</gsd:FaxNumberOfReportingEntity>
  <gsd:HomepageOfReportingEntity contextRef="ctx1">www.pfizer.dk</gsd:HomepageOfReportingEntity>
  <gsd:AddressOfReportingEntityStreetName contextRef="ctx1" xml:lang="da">Lautrupvang</gsd:AddressOfReportingEntityStreetName>
  <gsd:AddressOfReportingEntityStreetBuildingIdentifier contextRef="ctx1" xml:lang="da">8</gsd:AddressOfReportingEntityStreetBuildingIdentifier>
  <gsd:AddressOfReportingEntityPostCodeIdentifier contextRef="ctx1" xml:lang="da">2750</gsd:AddressOfReportingEntityPostCodeIdentifier>
  <gsd:AddressOfReportingEntityDistrictName contextRef="ctx1" xml:lang="da">Ballerup</gsd:AddressOfReportingEntityDistrictName>
  <gsd:AddressOfReportingEntityCountry contextRef="ctx1" xml:lang="da">Denmark</gsd:AddressOfReportingEntityCountry>
  <gsd:ReportingPeriodStartDate contextRef="ctx1">2020-12-01</gsd:ReportingPeriodStartDate>
  <gsd:ReportingPeriodEndDate contextRef="ctx1">2021-11-30</gsd:ReportingPeriodEndDate>
  <gsd:DateOfGeneralMeeting contextRef="ctx1">2022-04-28</gsd:DateOfGeneralMeeting>
  <gsd:NameAndSurnameOfChairmanOfGeneralMeeting contextRef="ctx1" xml:lang="da">Nicholas William Boe Stenderup</gsd:NameAndSurnameOfChairmanOfGeneralMeeting>
  <sob:StatementByExecutiveAndSupervisoryBoards contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Statement by the Board of Directors and the Executive Board&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</sob:StatementByExecutiveAndSupervisoryBoards>
  <sob:IdentificationOfApprovedAnnualReport contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;The Board of Directors and the Executive Board have today discussed and approved the annual report of Pfizer ApS for the financial year 1 December 2020 – 30 November 2021.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</sob:IdentificationOfApprovedAnnualReport>
  <sob:ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;The annual report has been prepared in accordance with the Danish Financial Statements Act.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</sob:ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement>
  <sob:ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;It is our opinion that the financial statements give a true and fair view of the Company's assets, liabilities and financial position at 30 November 2021 and of the results of the Company's operations for the financial year 1 December 2020 – 30 November 2021.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</sob:ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults>
  <sob:ManagementsStatementAboutManagementsReview contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;In our opinion, the Management's review gives a fair review of the development in the Company's operations and financial matters and the results of the Company's financial position.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</sob:ManagementsStatementAboutManagementsReview>
  <sob:RecommendationForApprovalOfAnnualReportByGeneralMeeting contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;We recommend that the annual report be approved at the annual general meeting.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</sob:RecommendationForApprovalOfAnnualReportByGeneralMeeting>
  <sob:PlaceOfSignatureOfStatement contextRef="ctx1" xml:lang="da">Ballerup</sob:PlaceOfSignatureOfStatement>
  <sob:DateOfApprovalOfAnnualReport contextRef="ctx1">2022-04-28</sob:DateOfApprovalOfAnnualReport>
  <arr:IndependentAuditorsReportsAudit contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Independent auditor’s report&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</arr:IndependentAuditorsReportsAudit>
  <arr:AddresseeOfAuditorsReportOnAuditedFinancialStatements contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;To the shareholders of Pfizer ApS&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</arr:AddresseeOfAuditorsReportOnAuditedFinancialStatements>
  <arr:OpinionOnAuditedFinancialStatements contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Opinion&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;We have audited the financial statements of Pfizer ApS for the financial year 1 December 2020 – 30 November 2021 comprising income statement, balance sheet, statement of changes in equity and notes. The financial statements are prepared in accordance with the Danish Financial Statements Act.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;In our opinion, the financial statements give a true and fair view of the Company's assets, liabilities and financial position at 30 November 2021 and of the results of the Company's operations for the financial year 1 December 2020 – 30 November 2021 in accordance with the Danish Financial Statements Act.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</arr:OpinionOnAuditedFinancialStatements>
  <arr:DescriptionOfQualificationsOfAuditedFinancialStatements contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Basis for opinion&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these rules and requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</arr:DescriptionOfQualificationsOfAuditedFinancialStatements>
  <arr:StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatements contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Management's responsibility for the financial statements&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control that Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;In preparing the financial statements, Management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</arr:StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatements>
  <arr:StatementOfAuditorsResponsibilityForAuditAndAuditPerformed contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Auditor's responsibilities for the audit of the financial statements&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Our objectives are to obtain reasonable assurance as to whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements in Denmark will always detect a material misstatement when it exists. Misstatements may arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of financial statement users made on the basis of these financial statements.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;— identify and assess the risks of material misstatement of the company financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;— obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;— evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;— conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;— evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</arr:StatementOfAuditorsResponsibilityForAuditAndAuditPerformed>
  <arr:StatementOnManagementsReviewAuditorsReportOnAuditedFinancialStatements contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Statement on the Management's review&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Management is responsible for the Management's review.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Our opinion on the financial statements does not cover the Management's review, and we do not express any form of assurance conclusion thereon.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;In connection with our audit of the financial statements, our responsibility is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Moreover, it is our responsibility to consider whether the Management's review provides the information required under the Danish Financial Statements Act.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Based on the work we have performed, we conclude that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statement Act. We did not identify any material misstatement of the Management's review&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</arr:StatementOnManagementsReviewAuditorsReportOnAuditedFinancialStatements>
  <arr:SignatureOfAuditorsPlace contextRef="ctx1" xml:lang="da">Copenhagen</arr:SignatureOfAuditorsPlace>
  <arr:SignatureOfAuditorsDate contextRef="ctx1">2022-04-28</arr:SignatureOfAuditorsDate>
  <mrv:InformationOnCalculationOfKeyFiguresAndFinancialRatios contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Financial highlights&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br&gt;&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;The financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios "Recommendations and Ratios".&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br&gt;&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;The financial ratios stated in the survey of financial highlights have been calculated as follows&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Operating profit ratio = Operating profit X 100 / Revenue&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Return on investment = Operating profit X 100 / Average invested capital&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Current ratio = Current assets X 100 / Total equity and liabilities at year end&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Equity ratio = Equity at year end X 100 / Total equity and liabilities at year end&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Return on average equity = Profit for the year X 100 / Average equity&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mrv:InformationOnCalculationOfKeyFiguresAndFinancialRatios>
  <fsa:Revenue contextRef="ctx1" unitRef="vDKK" decimals="-3">1580587000</fsa:Revenue>
  <fsa:ProfitLossFromOrdinaryOperatingActivities contextRef="ctx1" unitRef="vDKK" decimals="-3">139675000</fsa:ProfitLossFromOrdinaryOperatingActivities>
  <fsa:ResultsFromNetFinancials contextRef="ctx1" unitRef="vDKK" decimals="-3">-1488000</fsa:ResultsFromNetFinancials>
  <fsa:ProfitLoss contextRef="ctx1" unitRef="vDKK" decimals="-3">106063000</fsa:ProfitLoss>
  <mrv:OperatingMargin contextRef="ctx1" unitRef="pure" decimals="3">0.088</mrv:OperatingMargin>
  <mrv:ReturnOnInvestedCapital contextRef="ctx1" unitRef="pure" decimals="3">0.341</mrv:ReturnOnInvestedCapital>
  <mrv:EquityRatio contextRef="ctx1" unitRef="pure" decimals="3">0.616</mrv:EquityRatio>
  <fsa:AverageNumberOfEmployees contextRef="ctx1" unitRef="pure" decimals="0">119</fsa:AverageNumberOfEmployees>
  <mrv:ManagementsReview contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Management's review&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br&gt;&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Business Restructuring&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;In November 2021, the company has merged with its sister company Pfizer PFE ApS through a “Immediate-merger” with a retroactive effective date of 1st December 2020 as part of the “Smaller and more focused company initiative”.The merger has taken place in accordance with the accounting rules "book value method". The change is presented directly on equity at the beginning, as a net effect as a result of the merger and acquisitions according to the merger method. No comparative figures are adjusted.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Turnover in Pfizer ApS increased in 2020/21 from DKK 320 million to DKK 1,6 billion. The increase is mainly driven by the launch of a new vaccine against COVID-19. Also the discontinuing company Pfizer PFE contributed with revenue increase.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Operating Review&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;The operating profit increased by DKK 115,3 million compared to 2019/20, with operating profit being DKK 139,7 million in 2020/21. The result for the year is satisfactory, with a turnover and operating profit within the range of expectations set for 2020/21.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Marketing and Distribution costs increased by DKK 23,4 million compared to prior year. Main driver is due to merger with Pfizer PFE and additional cost in the Vaccine Business.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Development expenses increased by DKK 3,7 million compared to prior year, mainly due to the merger with Pfizer PFE, but also increased cost to medical studies.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Administrative expenses are at the same level.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;The result for the year is satisfactory.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Financial position&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;The Company's share capital and reserves amounted to DKK 483 million at year end 2020/21, which is 61,6% of the balance sheet total.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Research and development activities&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Research and development activities within the Biopharma division of Pfizer ApS comprise clinical trials, regulatory affairs, drug safety and medical affairs. The Pharmaceutical division of Pfizer ApS only performs research and development on behalf of other group enterprises.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Pfizer ApS does not acquire ownership to intellectual rights.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Outlook&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;For 2022 the Company expects revenue and profit for the year to increase. This will be largely driven by continuous growth of Comirnaty/COVID vaccine as well as top medicines and new launches (Eliquis, Xeljanz and Vyndaqel), partially offset by declining trends in Oncology (LoE and price impact on BioSims) and Vaccines excl mRNA.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;The prescription activity is expected to grow due to increased productivity in the secondary care and market growth as a result of aging population. The industry as a whole in Denmark is exposed to competition from parallel importers, biosimilar entries and generic substitution. At the same time, public health costs are under supervision.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Direct expenses are expected to increase in 2022 but by less than the expected increase in revenues. The increase is expected to be in the low single digit percent range and driven by investments in new products partially offset by reductions in spend on products in later stages of their lifecycle.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Events after the balance sheet date&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;No events have occurred after the balance sheet date significantly affecting the Company's financial position.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mrv:ManagementsReview>
  <mrv:StatementOfCorporateSocialResponsibility contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Statement on social responsibility §99 a&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Activities&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Pfizer Inc. and its worldwide affiliates is a research-based, global biopharmaceutical company. Pfizer works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. In the context of its global operations, Pfizer applies science and global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products in order to fulfill Pfizer’s purpose: Breakthroughs that change patients’ lives.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Pfizer ApS is a fully owned subsidiary of Pfizer Inc. and performs sales and marketing functions and purchase finished products from supply point companies for resale to third parties. Pfizer ApS operates as non-exclusive distributor in Denmark, selling to local wholesalers, pharmacies and government facilities, as well as to a third-party distributor in Iceland. As local market company it utilizes technical materials prepared centrally by the R&amp;amp;D and Commercial organizations to present scientific data and information to explain the approved uses, benefits and risks of Pfizer’s products.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Environmental, Social and Governance (ESG)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Pfizer’s commits to enhance stakeholder awareness of our priority Environmental, Social and Governance (ESG) issues and disclose how our performance on non-financial metrics is contributing to long-term value creation and a sustainable, responsible and patient-centric business model. At the heart of Pfizer’s ESG approach is the simple idea that our values and commitment to long-term sustainability is the way we strive to responsibly fulfil our purpose – breakthroughs that change patients’ lives – build trust and take accountability for the impact we make on society.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Environmental&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Pfizer is a company driven by science. For the past 20 years, we have taken a proactive approach to environmental sustainability. We have taken several voluntary steps that have allowed us to reduce our direct CO2-emissions with over 60 percent since 2000.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;In 2021, we updated our SBTi-validated sustainability goals to reflect the need for further action. Our current goal is to be carbon neutral across internal operations by 2030. To do this, we need a 46 percent reduction in our direct CO2-emissions from a 2019-baseline. We are also committing to purchase 100 percent renewable energy and use climate credits to supplement when needed.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;By 2025 we will also be reducing our indirect CO2-emissions from transport and distribution by 10 percent and cutting our travel activity by 25 % from a 2019 baseline.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;As scope 3 emissions make up for more than 75 percent of Pfizer’s total emissions, we will also be increasing our focus on our suppliers. Sustainability criteria are already part of our vendor selection process, our contracts and they are used as a tool in our performance management.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Now we will go one step further and ask our suppliers to establish a baseline for their CO2-emissions by the end of 2022, and we will ask them to implement SBTi-validated reduction targets by the end of 2025. The goal for 2025 is that 64 percent of our purchases come from suppliers who already have- or are implementing SBTi-validated targets.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Going forward, we will also be participating in Energize, a collaboration between 10 global pharmaceutical companies that intends to engage suppliers in emission reductions across the entire pharmaceutical value chain through purchasing renewable and sustainable energy. The Energizeprogram will ensure that suppliers of the pharmaceutical industry have access to resources and education within sustainable energy and contracting. We expect that this will help suppliers with their green transition.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Pfizer in Denmark will be working to support these global goals in several ways: We will be reducing travel according to the global goals; we will be implementing a hybrid model for work, encouraging colleagues to continue work from home when it’s meaningful, thus reducing emissions from transport; and we will renovate our office to become more environmentally sustainable. Furthermore, we have an ongoing project looking into ways to make the Danish organization and our ways of working more environmentally sustainable. Finally, we are working with our trade association and other stakeholders to find ways to support a more environmentally sustainable health care sector.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Social&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;The COVID-19 pandemic continues to introduce uncertainty and fluid challenges, heightening our business imperative to harness scientific innovation to help create a healthier, more equitable world for all. While we are continually redoubling our efforts to address COVID-19 as it evolves, we remain focused on helping to address the burden on individuals, their families, and communities of other equally debilitating infectious and chronic diseases. Through our partnerships and programs, we aim to expand affordable access to our breakthrough medicines and vaccines, particularly among underserved communities. Our societal priorities extend to people across the globe and within our own workforce and supply chain, as we invest in our human capital and work to advance diversity, equity, and inclusion.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;• Locally, an estimated 67% of Denmark's populations have been treated by a Pfizer product. 3.9 m are vaccinated with Comirnaty, Pfizer´s COVID-19 vaccine, making Pfizer a significant contributor to the health of the Danish population.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;• In Pfizer Denmark, we support Pfizer’s global goals of equity and diversity. In our organization, we have 68% female representation and 32% male. The company’s leadership team consists of 6 women and 7 men.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;• 21% Clinical success rate (first-inhuman to approval) for Pfizer new molecular entities by end of 2021.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Governance&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;We behave ethically and thoughtfully in everything that we do, owning our responsibility to change lives for the better. As part of this responsibility, Pfizer prioritizes safety, quality, and transparency in our operations. Our governance structure supports proactive business-led quality and compliance built around elements of effective risk management. Pfizer policy prohibits all forms of bribery and corruption, whether by colleagues or our business partners. Colleagues and business partners must never offer, promise, authorize, or provide a payment or benefit that is intended to improperly influence a government official, healthcare professional, or any other person, including commercial entities and individuals, in exercising their responsibilities colleagues and certain third parties receive risk based, role-specific training on our Code of Conduct and other key areas, including ethical standards, responsible marketing and advertising practices, and antibribery /anti-corruption training, upon hire and regularly thereafter (normally every one to two years), to reinforce our policies and commitment to integrity.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;The Company’s ultimate parent company Pfizer Inc. created the program My Anti-Corruption Policy and Procedures (MAPP) to serve as guide on how to conduct Pfizer’s business while complying with anti-corruption laws. MAPP provides the tools Pfizer employees need to address bribery and corruption risks in their interactions with healthcare professionals, government regulators, and business partners.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;To ensure compliance with country-specific restrictions on interactions with Government Officials and Healthcare Professionals (HCP) in Denmark, the MAPP policy contains a Country Annex which address the following: lists of categories of Government Officials, HCP’s and Key Decision-Making Entities, a list of circumstances that automatically make a Government Official, country-specific information on local restrictions in dealings with Government Officials and HCPs and, any locally customized versions of some appendices (e.g. Sample Invitation Letter, Funding Confirmation Letter, etc.) tailored to comply with the requirements in Denmark.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;During 2021, the Company has worked with the Global MAPP Transformation Initiative which is comprised of three components: streamlined MAPP policy, transforming MAPP process and establishment of MAPP Navigator as a replacement of ACM pre-approval system. The MAPP Country Annex has been reviewed and updated to be aligned with the new MAPP program. The review will also be performed on an annual basis. MAPP process has been transformed by involving significant number of stakeholder groups (Commercial, GCO, Legal, Compliance, BT, Procurement, Finance) and the implementation of the global system MAPP-navigator will support the new MAPP process and drive automation. Go live date is March 2022.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;The Group’s Corporate Internal Audit department performs periodic testing of activities under the MAPP program. No findings were identified for the Company during 2021.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mrv:StatementOfCorporateSocialResponsibility>
  <mrv:StatementOfTargetFiguresAndPoliciesForTheUnderrepresentedGender contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Target figures regarding the under-represented gender in the Board of Directors, §99 b&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;In accordance with section §99 b of the Danish Financial Statements Act, we have adopted a culture of diversity and inclusion. There is no disparity between the genders both at the Board and managerial levels. Our Board of Directors consists of 3 members, of which 1 female and 2 males. As this ratio is considered balanced in regard to 99b, no target has been set to decrease the gender underrepresentation.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;In respect to other management levels, no gender is underrepresented with less than 40% for FY21, thus no specific policy has been adopted.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mrv:StatementOfTargetFiguresAndPoliciesForTheUnderrepresentedGender>
  <mrv:StatementOfPolicyForDataEthics contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Data Ethics statement §99 d&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Pfizer is committed to the responsible and transparent use and protection of personal data entrusted to us by patients, customers, employees and others. We provide our employees and contractors with training on global privacy principles in accordance with our commitment to respect and safeguard personal data. Our privacy practices are governed by our Global Privacy Committee, a crossfunctional governance body composed of senior-level leaders who provide oversight and guidance that informs company practices. Additionally, our Global Privacy Office maintains an enterprise-wide policy and standards that guide the collection, maintenance and protection of personal data and consider the legal and regulatory requirements where we do business.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Examples of the practices we follow to help ensure the integrity of our data privacy processes include&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;• Collecting and using the minimum amount of personal data necessary to achieve our business purposes.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;• Sharing personal data only with individuals who have a legitimate need for it and will protect it.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;• Maintaining appropriate administrative, technical and organizational security measures to protect personal data.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;• Training our employees on the responsible use of personal information&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mrv:StatementOfPolicyForDataEthics>
  <fsa:CostOfSales contextRef="ctx1" unitRef="vDKK" decimals="-3">1324422000</fsa:CostOfSales>
  <fsa:GrossResult contextRef="ctx1" unitRef="vDKK" decimals="-3">256165000</fsa:GrossResult>
  <fsa:DistributionCosts contextRef="ctx1" unitRef="vDKK" decimals="-3">129450000</fsa:DistributionCosts>
  <fsa:DevelopmentExpenditure contextRef="ctx1" unitRef="vDKK" decimals="-3">63905000</fsa:DevelopmentExpenditure>
  <fsa:AdministrativeExpenses contextRef="ctx1" unitRef="vDKK" decimals="-3">32204000</fsa:AdministrativeExpenses>
  <fsa:OtherOperatingIncome contextRef="ctx1" unitRef="vDKK" decimals="-3">109069000</fsa:OtherOperatingIncome>
  <fsa:OtherFinanceIncome contextRef="ctx1" unitRef="vDKK" decimals="-3">-1488000</fsa:OtherFinanceIncome>
  <fsa:ProfitLossFromOrdinaryActivitiesBeforeTax contextRef="ctx1" unitRef="vDKK" decimals="-3">138187000</fsa:ProfitLossFromOrdinaryActivitiesBeforeTax>
  <fsa:TaxExpense contextRef="ctx1" unitRef="vDKK" decimals="-3">32124000</fsa:TaxExpense>
  <fsa:ProfitLossFromContinuingOperations contextRef="ctx1" unitRef="vDKK" decimals="-3">106063000</fsa:ProfitLossFromContinuingOperations>
  <fsa:ProfitLossFromDiscontinuedOperations contextRef="ctx1" unitRef="vDKK" decimals="-3">0</fsa:ProfitLossFromDiscontinuedOperations>
  <fsa:StatementOfChangesInEquity contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;&lt;b&gt;Statement of Changes in Equity&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="36%" colspan="1" align="left" valign="middle" &gt;&lt;b&gt;DKK'000&lt;/b&gt;&lt;/td&gt;&lt;td width="13%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;Share Capital&lt;/b&gt;&lt;/td&gt;&lt;td width="18%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;Retained Earnings&lt;/b&gt;&lt;/td&gt;&lt;td width="19%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;Proposed dividend&lt;/b&gt;&lt;/td&gt;&lt;td width="14%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="36%" colspan="1" align="left" valign="middle" &gt;Equity at 1 December 2020&lt;/td&gt;&lt;td width="13%" align="right" valign="middle" &gt;250.771&lt;/td&gt;&lt;td width="18%" align="right" valign="middle" &gt;51.439&lt;/td&gt;&lt;td width="19%" align="right" valign="middle" &gt;0&lt;/td&gt;&lt;td width="14%" align="right" valign="middle" &gt;302.210&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="36%" colspan="1" align="left" valign="middle" &gt;Equity merged from Pfizer PFE ApS&lt;/td&gt;&lt;td width="13%" align="right" valign="middle" &gt;1&lt;/td&gt;&lt;td width="18%" align="right" valign="middle" &gt;74.770&lt;/td&gt;&lt;td width="19%" align="right" valign="middle" &gt;0&lt;/td&gt;&lt;td width="14%" align="right" valign="middle" &gt;74.771&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="36%" colspan="1" align="left" valign="middle" &gt;Transferred from profit for the year&lt;/td&gt;&lt;td width="13%" align="right" valign="middle" &gt;0&lt;/td&gt;&lt;td width="18%" align="right" valign="middle" &gt;106.063&lt;/td&gt;&lt;td width="19%" align="right" valign="middle" &gt;0&lt;/td&gt;&lt;td width="14%" align="right" valign="middle" &gt;106.063&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="36%" colspan="1" align="left" valign="middle" &gt;Equity at 30 November2021&lt;/td&gt;&lt;td width="13%" align="right" valign="middle" &gt;250.772&lt;/td&gt;&lt;td width="18%" align="right" valign="middle" &gt;232.272&lt;/td&gt;&lt;td width="19%" align="right" valign="middle" &gt;0&lt;/td&gt;&lt;td width="14%" align="right" valign="middle" &gt;483.044&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:StatementOfChangesInEquity>
  <fsa:InformationOnReportingClassOfEntity contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;The annual report for 2020/21 has been prepared in accordance with the provisions applying to class C (large) enterprises under the Danish Financial Statements Act.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:InformationOnReportingClassOfEntity>
  <fsa:AccountingPoliciesAreUnchangedFromPreviousPeriod contextRef="ctx1">true</fsa:AccountingPoliciesAreUnchangedFromPreviousPeriod>
  <fsa:DescriptionOfMethodsOfTranslationOfForeignCurrencies contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Foreign currency translation&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Transactions in foreign currencies are translated at the exchange rates at the transaction date. Foreign exchange differences arising between the exchange rates at the transaction date and at the date of payment are recognised in the income statement as interest income or expense and similar items.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Receivables and payables and other monetary items denominated in foreign currencies that have not been settled at the balance sheet date are translated at the exchange rates at the balance sheet date. The difference between the exchange rates at the balance sheet date and at the date at which the receivable or payable arose or was recognised in the latest financial statements is recognised in the income statement as interest income or expense and similar items.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DescriptionOfMethodsOfTranslationOfForeignCurrencies>
  <fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfRevenue contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Revenue&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Revenue from the sale of goods for resale is recognized in the income statement provided that delivery and transfer of risk to the buyer has taken place before year end and that the income can be reliably measured and is expected to be received. Revenue is measured exclusive of VAT and taxes related to sales.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfRevenue>
  <fsa:InformationOnSegments contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Segment information&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Segment information Information is provided on business segments. Segment information is based on the Company's accounting policies, risks and internal financial management.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:InformationOnSegments>
  <fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCostOfSales contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Cost of sales&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Cost of sales comprises the cost of goods and services sold during the year.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCostOfSales>
  <fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfDistributionCosts contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Marketing and distribution expenses&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Marketing and distribution expenses Costs incurred in marketing and distributing goods sold during the year and in conducting sales campaigns etc. during the year are recognised as marketing and distribution expenses. Also, costs relating to sales staff, advertising, exhibitions and depreciation are recognised as marketing and distribution expenses.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfDistributionCosts>
  <fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfResearchAndDevelopmentExpendituresRecognisedAsExpenses contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Development expenses&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Development expenses of the Pharmaceutical division comprise costs related to clinical trials, regulatory affairs, drug safety and medical affairs. The Pharmaceutical division of Pfizer ApS only performs research and development on behalf of other group enterprises. Development expenses of the Consumer division comprise product development including product design, nutritional science (medical affairs/clinical trials), project management and regulatory affairs.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfResearchAndDevelopmentExpendituresRecognisedAsExpenses>
  <fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfAdministrativeExpenses contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Administrative expenses&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Administrative expenses comprise expenses incurred during the year for management and administration, including expenses for administrative staff, office premises and office expenses, and depreciation.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfAdministrativeExpenses>
  <fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfOtherOperatingIncomeAndExpenses contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Other operating income and expenses&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Other operating income and expenses comprise items secondary to the principal activities of the enterprise. Other operating income mainly includes income from research and development, marketing and administrative services provided to other Pfizer entities. Gains or losses on the divestment of activities are calculated as the difference between the sales amount and the carrying amount of net assets at the date of disposal, and recognised as either other operating income or expenses.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfOtherOperatingIncomeAndExpenses>
  <fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfFinanceIncomeAndExpenses contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Interest income and expense and similar items&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Interest income and expense and similar items comprise interest income and expense, gains and losses on payables and transactions denominated in foreign currencies as well as surcharges and refunds under the on-account tax scheme etc.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfFinanceIncomeAndExpenses>
  <fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxExpenses contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Tax on profit for the year&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Tax for the year comprises current tax and changes in deferred tax for the year. The tax expense relating to the profit/loss for the year is recognised in the income statement, and the tax expense relating to changes directly recognised in equity is recognised directly in equity.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxExpenses>
  <fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfPropertyPlantAndEquipment contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Property, plant and equipment&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Property, plant and equipment are measured at cost less accumulated depreciation and impairment loss. Cost comprises the purchase price and any costs directly attributable to the acquisition until the date when the asset is available for use.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Depreciation is provided on a straight-line basis over the expected useful life of the assets. The expected useful life is as follows&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Leasehold improvements, fixtures and fittings, tools and equipment: 8-12 years&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;The useful life and residual value are reassessed annually. Changes are treated as accounting estimates, and the effect on depreciation is recognised prospectively.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Fixed assets under construction are recognised and measured at cost at the balance sheet date. Upon entry into service, the cost is transferred to the relevant group of property, plant and equipment&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Depreciation is recognised in the income statement as marketing and distribution costs, development costs and administrative expenses, respectively.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfPropertyPlantAndEquipment>
  <fsa:DescriptionOfMethodsOfAmortisationOfNoncurrentAssets contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Impairment&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;The carrying amount of property, plant and equipment is subject to an annual impairment test besides depreciation.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;When there is an indication that assets may be impaired, an impairment test is made of each asset or group of assets, respectively. Impairment is made to the lower of recoverable amount of the asset and the carrying amount.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DescriptionOfMethodsOfAmortisationOfNoncurrentAssets>
  <fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfInventories contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Inventories&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Inventories are measured at cost in accordance with the FIFO method. Where the net realisable value is lower than cost, inventories are written down to this lower value. The net realisable value of inventories is calculated as the sales amount less costs of completion and costs necessary to make the sale and is determined taking into account marketability, obsolescence and development in expected sales price.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfInventories>
  <fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfReceivables contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Receivables&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Receivables are measured at amortised cost. Provisions are made for anticipated losses.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfReceivables>
  <fsa:DescriptionOfMethodsOfPrepayments contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Prepayments&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Prepayments comprise costs incurred concerning subsequent financial years.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DescriptionOfMethodsOfPrepayments>
  <fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfEquity contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Capital and reserves - dividends&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Proposed dividends are recognised as a liability at the date when they are adopted at the annual general meeting (declaration date). The expected dividend payment for the year is disclosed as a separate item under capital and reserves.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfEquity>
  <fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfAssetsAndLiabilities contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Corporation tax and deferred tax&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Current tax payable and receivable is recognised in the balance sheet as tax computed on the taxable income for the year, adjusted for tax on the taxable income of prior years and for tax paid on account.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Deferred tax is measured using the balance sheet liability method on all temporary differences between the carrying amount and the tax base of assets and liabilities. However, deferred tax is not recognised on temporary differences relating to goodwill which is not deductible for tax purposes and on office premises and other items where temporary differences, apart from business combinations, arise at the date of acquisition without affecting either profit/loss for the year or taxable income. Where alternative tax rules can be applied to determine the tax base, deferred tax is measured based on the planned use of the asset or settlement of the liability, respectively.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Deferred tax assets, including the tax base of tax loss carry forwards, are recognised under investments at the expected value of their utilisation; either as a set-off against tax on future income or as a set-off against deferred tax liabilities in the same legal tax entity and jurisdiction.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Deferred tax is measured according to the tax rules and at the tax rates applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfAssetsAndLiabilities>
  <fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfOtherProvisions contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Other provisions&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Provisions comprise anticipated costs relating to returned goods and restructuring provisions. Provisions for returns are measured and recognised based on Management's experiences of returned goods.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfOtherProvisions>
  <fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfLiabilitiesOtherThanProvisions contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Financial liabilities&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Financial liabilities, comprising trade payables and amounts owed to group enterprises are measured at amortised cost. Other liabilities are measured at net realisable value.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfLiabilitiesOtherThanProvisions>
  <fsa:ExplanationOfNotDisclosingCashFlowsStatements contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Cash flow statement&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;Pfizer ApS has not prepared a cash flow statement because the Company is included in the consolidated cash flow statement for the ultimate parent company Pfizer Inc. which can be found in the “for Investors” section under 2021 Financial Report at www.pfizer.com&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:ExplanationOfNotDisclosingCashFlowsStatements>
  <fsa:InformationOnOperatingSegmentsAndGeographicalMarkets contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;&lt;b&gt;Noter&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;&lt;b&gt;Segment information&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;&lt;b&gt;Geographical breakdown&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="66%" colspan="2" align="left" valign="middle" &gt;&lt;b&gt;DKK'000&lt;/b&gt;&lt;/td&gt;&lt;td width="19%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;Denmark Pharmaceutical Products&lt;/b&gt;&lt;/td&gt;&lt;td width="6%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;Iceland&lt;/b&gt;&lt;/td&gt;&lt;td width="9%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;&lt;b&gt;2020/21&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="66%" colspan="2" align="left" valign="middle" &gt;Revenue&lt;/td&gt;&lt;td width="19%" align="right" valign="middle" &gt;1.475.555&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;105.033&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;1.580.587&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;&lt;b&gt;2019/20&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="66%" colspan="2" align="left" valign="middle" &gt;Revenue&lt;/td&gt;&lt;td width="19%" align="right" valign="middle" &gt;285.157&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;34.783&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;319.940&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;All revenue is related to the sale of prescription medicine.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:InformationOnOperatingSegmentsAndGeographicalMarkets>
  <fsa:DisclosureOfEmployeeBenefitsExpense contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;&lt;b&gt;Staff costs&lt;/b&gt;&lt;/td&gt;&lt;td width="6%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;2020/21&lt;/b&gt;&lt;/td&gt;&lt;td width="9%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;2019/20&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" &gt;&lt;/td&gt;&lt;td width="5%" &gt;&lt;/td&gt;&lt;td width="19%" &gt;&lt;/td&gt;&lt;td width="6%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;DKK'000&lt;/b&gt;&lt;/td&gt;&lt;td width="9%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;DKK'000&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Wages &amp; Salaries&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;123.402&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;104.645&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Pensions&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;10.578&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;9.249&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Other Social Security Costs&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;1.059&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;716&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" &gt;&lt;/td&gt;&lt;td width="5%" &gt;&lt;/td&gt;&lt;td width="19%" &gt;&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;135.039&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;114.610&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;Staff Costs are recognised as follows in the financial statements&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Marketing and distribution costs&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;83.796&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;66.817&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Research &amp; Development Expenses&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;38.788&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;36.501&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Administrative Expenses&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;12.455&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;11.292&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" &gt;&lt;/td&gt;&lt;td width="5%" &gt;&lt;/td&gt;&lt;td width="19%" &gt;&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;135.039&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;114.610&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;Average Number of Employees&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" &gt;&lt;/td&gt;&lt;td width="5%" &gt;&lt;/td&gt;&lt;td width="19%" &gt;&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;119&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;107&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;Pursuant to Section 98b of the Danish Financial Statements Act, remuneration to Management is not disclosed. No emoluments have been paid to the Board of Directors.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DisclosureOfEmployeeBenefitsExpense>
  <fsa:DisclosureOfDepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;&lt;b&gt;Depreciation and impairment loss&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" &gt;&lt;/td&gt;&lt;td width="5%" &gt;&lt;/td&gt;&lt;td width="19%" &gt;&lt;/td&gt;&lt;td width="6%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;2020/21&lt;/b&gt;&lt;/td&gt;&lt;td width="9%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;2019/20&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" &gt;&lt;/td&gt;&lt;td width="5%" &gt;&lt;/td&gt;&lt;td width="19%" &gt;&lt;/td&gt;&lt;td width="6%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;DKK'000&lt;/b&gt;&lt;/td&gt;&lt;td width="9%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;DKK'000&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;&lt;b&gt;Property, plant and equipment&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Depreciation for the year&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;87&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;481&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" &gt;&lt;/td&gt;&lt;td width="5%" &gt;&lt;/td&gt;&lt;td width="19%" &gt;&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;87&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;481&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;Depreciation &amp; impairment losses are recognisedas follows in the financial statements&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Development Expenses&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;87&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;481&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" &gt;&lt;/td&gt;&lt;td width="5%" &gt;&lt;/td&gt;&lt;td width="19%" &gt;&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;87&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;481&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DisclosureOfDepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss>
  <fsa:InformationOnAuditorsFees contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;&lt;b&gt;Fees to auditors appointed at the annual general meeting&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" &gt;&lt;/td&gt;&lt;td width="5%" &gt;&lt;/td&gt;&lt;td width="19%" &gt;&lt;/td&gt;&lt;td width="6%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;2020/21&lt;/b&gt;&lt;/td&gt;&lt;td width="9%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;2019/20&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" &gt;&lt;/td&gt;&lt;td width="5%" &gt;&lt;/td&gt;&lt;td width="19%" &gt;&lt;/td&gt;&lt;td width="6%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;DKK'000&lt;/b&gt;&lt;/td&gt;&lt;td width="9%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;DKK'000&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Statutory audit&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;623&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;443&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Other&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;25&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" &gt;&lt;/td&gt;&lt;td width="5%" &gt;&lt;/td&gt;&lt;td width="19%" &gt;&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;648&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;443&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:InformationOnAuditorsFees>
  <fsa:DisclosureOfOtherOperatingIncome contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;&lt;b&gt;Other operating income/expenses, net&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" &gt;&lt;/td&gt;&lt;td width="5%" &gt;&lt;/td&gt;&lt;td width="19%" &gt;&lt;/td&gt;&lt;td width="6%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;2020/21&lt;/b&gt;&lt;/td&gt;&lt;td width="9%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;2019/20&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" &gt;&lt;/td&gt;&lt;td width="5%" &gt;&lt;/td&gt;&lt;td width="19%" &gt;&lt;/td&gt;&lt;td width="6%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;DKK'000&lt;/b&gt;&lt;/td&gt;&lt;td width="9%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;DKK'000&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Sales &amp; Marketing Service&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;31.651&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;25.062&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Administrative Services&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;10.126&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;9.023&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Development Services&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;67.293&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;63.768&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" &gt;&lt;/td&gt;&lt;td width="5%" &gt;&lt;/td&gt;&lt;td width="19%" &gt;&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;109.070&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;97.853&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DisclosureOfOtherOperatingIncome>
  <fsa:DisclosureOfOtherFinanceIncome contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;&lt;b&gt;Net interest income and expenses and similar items&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" &gt;&lt;/td&gt;&lt;td width="5%" &gt;&lt;/td&gt;&lt;td width="19%" &gt;&lt;/td&gt;&lt;td width="6%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;2020/21&lt;/b&gt;&lt;/td&gt;&lt;td width="9%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;2019/20&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" &gt;&lt;/td&gt;&lt;td width="5%" &gt;&lt;/td&gt;&lt;td width="19%" &gt;&lt;/td&gt;&lt;td width="6%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;DKK'000&lt;/b&gt;&lt;/td&gt;&lt;td width="9%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;DKK'000&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Foreign exchange adjustments&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;-412&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;724&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Interest expenses&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;-981&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;-759&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Bank charges&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;-95&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;-65&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" &gt;&lt;/td&gt;&lt;td width="5%" &gt;&lt;/td&gt;&lt;td width="19%" &gt;&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;-1.488&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;-100&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DisclosureOfOtherFinanceIncome>
  <fsa:DisclosureOfTaxExpenses contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;&lt;b&gt;Tax on the profit for the year&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" &gt;&lt;/td&gt;&lt;td width="5%" &gt;&lt;/td&gt;&lt;td width="19%" &gt;&lt;/td&gt;&lt;td width="6%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;2020/21&lt;/b&gt;&lt;/td&gt;&lt;td width="9%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;2019/20&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" &gt;&lt;/td&gt;&lt;td width="5%" &gt;&lt;/td&gt;&lt;td width="19%" &gt;&lt;/td&gt;&lt;td width="6%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;DKK'000&lt;/b&gt;&lt;/td&gt;&lt;td width="9%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;DKK'000&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Corporation tax on profit for the year&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;31.337&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;5.760&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Adjustment for deferred tax&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;843&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;550&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Adjustments to taxes from prior years&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;-56&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;-3.750&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" &gt;&lt;/td&gt;&lt;td width="5%" &gt;&lt;/td&gt;&lt;td width="19%" &gt;&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;32.124&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;2.560&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DisclosureOfTaxExpenses>
  <fsa:DisclosureOfDiscontinuedOperations contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;&lt;b&gt;Profit from discontinued operations&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;During the year 2019/20, the Company transferred the consumer business division to GlaxoSmithKline (GSK). Profit after tax of the discontinued operations were recognised as a separate line in the income statement for 2019/20.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" &gt;&lt;/td&gt;&lt;td width="5%" &gt;&lt;/td&gt;&lt;td width="19%" &gt;&lt;/td&gt;&lt;td width="6%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;2020/21&lt;/b&gt;&lt;/td&gt;&lt;td width="9%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;2019/20&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" &gt;&lt;/td&gt;&lt;td width="5%" &gt;&lt;/td&gt;&lt;td width="19%" &gt;&lt;/td&gt;&lt;td width="6%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;DKK'000&lt;/b&gt;&lt;/td&gt;&lt;td width="9%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;DKK'000&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Revenue&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;0&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;19.418&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Cost of sales&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;0&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;-12.448&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Marketing and distribution expenses&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;0&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;-6.617&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Development expenses&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;0&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;-3.720&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Administrative expenses&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;0&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;-5.798&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" &gt;&lt;/td&gt;&lt;td width="5%" &gt;&lt;/td&gt;&lt;td width="19%" &gt;&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;&lt;b&gt;0&lt;/b&gt;&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;&lt;b&gt;-9.165&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Other operating income/expenses, net&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;0&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;7.577&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Profit from sale of discontinued operations&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;0&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;11.008&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;&lt;b&gt;Profit before tax&lt;/b&gt;&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;&lt;b&gt;0&lt;/b&gt;&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;&lt;b&gt;9.420&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Tax on profit for the year&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;0&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;-2.072&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;&lt;b&gt;Profit from discontinued operations for the year&lt;/b&gt;&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;&lt;b&gt;0&lt;/b&gt;&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;&lt;b&gt;7.348&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;&lt;b&gt;Assets and liabilities regarding discontinued operations specified in principal items&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" &gt;&lt;/td&gt;&lt;td width="5%" &gt;&lt;/td&gt;&lt;td width="19%" &gt;&lt;/td&gt;&lt;td width="6%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;2020/21&lt;/b&gt;&lt;/td&gt;&lt;td width="9%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;2019/20&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" &gt;&lt;/td&gt;&lt;td width="5%" &gt;&lt;/td&gt;&lt;td width="19%" &gt;&lt;/td&gt;&lt;td width="6%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;DKK'000&lt;/b&gt;&lt;/td&gt;&lt;td width="9%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;DKK'000&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Assets regarding discontinued operations&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;0&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;7.956&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Liabilities regarding discontinued operations&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;0&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;-2.072&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Net assets regarding discontinued operations&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;0&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;5.884&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DisclosureOfDiscontinuedOperations>
  <fsa:DisclosureOfPropertyPlantAndEquipment contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;&lt;b&gt;Property, plant and equipment&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" &gt;&lt;/td&gt;&lt;td width="5%" &gt;&lt;/td&gt;&lt;td width="19%" &gt;&lt;/td&gt;&lt;td width="6%" &gt;&lt;/td&gt;&lt;td width="9%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;Fixtures and fittings, tools and equipment&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" &gt;&lt;/td&gt;&lt;td width="5%" &gt;&lt;/td&gt;&lt;td width="19%" &gt;&lt;/td&gt;&lt;td width="6%" &gt;&lt;/td&gt;&lt;td width="9%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;DKK'000&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="91%" colspan="4" align="left" valign="middle" &gt;&lt;b&gt;Costs at 30 November 2020&lt;/b&gt;&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;&lt;b&gt;9.501&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="91%" colspan="4" align="left" valign="middle" &gt;Disposals for the year&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;-1.808&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="91%" colspan="4" align="left" valign="middle" &gt;&lt;b&gt;Costs at 30 November 2021&lt;/b&gt;&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;&lt;b&gt;7.693&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="91%" colspan="4" align="left" valign="middle" &gt;&lt;b&gt;Depreciationat 30 November 2020&lt;/b&gt;&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;&lt;b&gt;-9.035&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="91%" colspan="4" align="left" valign="middle" &gt;Depreciation&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;-87&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="91%" colspan="4" align="left" valign="middle" &gt;Reversal of depreciationon disposals&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="91%" colspan="4" align="left" valign="middle" &gt;&lt;b&gt;Depreciationat 30 November 2021&lt;/b&gt;&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;&lt;b&gt;-7.314&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="91%" colspan="4" align="left" valign="middle" &gt;&lt;b&gt;Carrying amount at 30 November 2021&lt;/b&gt;&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;&lt;b&gt;379&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DisclosureOfPropertyPlantAndEquipment>
  <fsa:DisclosureOfReceivables contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;&lt;b&gt;Corporation tax&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" &gt;&lt;/td&gt;&lt;td width="5%" &gt;&lt;/td&gt;&lt;td width="19%" &gt;&lt;/td&gt;&lt;td width="6%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;2020/21&lt;/b&gt;&lt;/td&gt;&lt;td width="9%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;2019/20&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" &gt;&lt;/td&gt;&lt;td width="5%" &gt;&lt;/td&gt;&lt;td width="19%" &gt;&lt;/td&gt;&lt;td width="6%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;DKK'000&lt;/b&gt;&lt;/td&gt;&lt;td width="9%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;DKK'000&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Tax on taxable income for the year&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;-31.337&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;-5.760&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Joint taxation adjustments&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;0&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;-1.319&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Tax payment on account&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;59.322&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;13.000&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Receivable/(Payable), outstanding from prior years&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;3.905&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Payable tax, outstandingfrom prior years&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;0&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;&lt;b&gt;Receivable corporation tax at 30 November&lt;/b&gt;&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;&lt;b&gt;31.890&lt;/b&gt;&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;&lt;b&gt;5.921&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DisclosureOfReceivables>
  <fsa:ExplanationOfPrepayments contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;&lt;b&gt;Prepayments&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" &gt;&lt;/td&gt;&lt;td width="5%" &gt;&lt;/td&gt;&lt;td width="19%" &gt;&lt;/td&gt;&lt;td width="6%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;2020/21&lt;/b&gt;&lt;/td&gt;&lt;td width="9%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;2019/20&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" &gt;&lt;/td&gt;&lt;td width="5%" &gt;&lt;/td&gt;&lt;td width="19%" &gt;&lt;/td&gt;&lt;td width="6%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;DKK'000&lt;/b&gt;&lt;/td&gt;&lt;td width="9%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;DKK'000&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Other prepayments&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;1.981&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;1.045&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" &gt;&lt;/td&gt;&lt;td width="5%" &gt;&lt;/td&gt;&lt;td width="19%" &gt;&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;1.981&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;1.045&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:ExplanationOfPrepayments>
  <fsa:InformationOnProvisionsForDeferredTax contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;&lt;b&gt;Deferred tax&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" &gt;&lt;/td&gt;&lt;td width="5%" &gt;&lt;/td&gt;&lt;td width="19%" &gt;&lt;/td&gt;&lt;td width="6%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;2020/21&lt;/b&gt;&lt;/td&gt;&lt;td width="9%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;2019/20&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" &gt;&lt;/td&gt;&lt;td width="5%" &gt;&lt;/td&gt;&lt;td width="19%" &gt;&lt;/td&gt;&lt;td width="6%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;DKK'000&lt;/b&gt;&lt;/td&gt;&lt;td width="9%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;DKK'000&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Deferred tax 1 December&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;2.780&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;3.330&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Adjustmentof deferred tax&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;-843&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;-550&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" &gt;&lt;/td&gt;&lt;td width="5%" &gt;&lt;/td&gt;&lt;td width="19%" &gt;&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;3.474&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;2.780&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;Deferred tax relates to plant and equipment, inventories, receivables, other provisions and other payables. The deferred tax asset is expected to be realisable within the foreseeable future.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:InformationOnProvisionsForDeferredTax>
  <fsa:DisclosureOfContributedCapital contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td width="100%" colspan="6" align="left" valign="middle" &gt;&lt;b&gt;Capital and reserves&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="6" align="left" valign="middle" &gt;The share capital comprises 250,772 thousand issued shares with a nominal value of 1 DKK each.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="6" align="left" valign="middle" &gt;The changes in share capital for the last 5 years can be specified as follows&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="58%" &gt;&lt;/td&gt;&lt;td width="5%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;2020/21&lt;/b&gt;&lt;/td&gt;&lt;td width="18%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;2019/20&lt;/b&gt;&lt;/td&gt;&lt;td width="6%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;2018/19&lt;/b&gt;&lt;/td&gt;&lt;td width="6%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;2017/18&lt;/b&gt;&lt;/td&gt;&lt;td width="7%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;2016/17&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="58%" colspan="1" align="left" valign="middle" &gt;Share capital at 1 December&lt;/td&gt;&lt;td width="5%" align="right" valign="middle" &gt;250.772&lt;/td&gt;&lt;td width="18%" align="right" valign="middle" &gt;250.771&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;250.771&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;250.771&lt;/td&gt;&lt;td width="7%" align="right" valign="middle" &gt;250.771&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="58%" colspan="1" align="left" valign="middle" &gt;Share capital at 30 November&lt;/td&gt;&lt;td width="5%" align="right" valign="middle" &gt;250.772&lt;/td&gt;&lt;td width="18%" align="right" valign="middle" &gt;250.771&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;250.771&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;250.771&lt;/td&gt;&lt;td width="7%" align="right" valign="middle" &gt;250.771&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DisclosureOfContributedCapital>
  <fsa:DisclosureOfOtherProvisions contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;&lt;b&gt;Other provisions&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" &gt;&lt;/td&gt;&lt;td width="5%" &gt;&lt;/td&gt;&lt;td width="19%" &gt;&lt;/td&gt;&lt;td width="6%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;2020/21&lt;/b&gt;&lt;/td&gt;&lt;td width="9%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;2019/20&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" &gt;&lt;/td&gt;&lt;td width="5%" &gt;&lt;/td&gt;&lt;td width="19%" &gt;&lt;/td&gt;&lt;td width="6%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;DKK'000&lt;/b&gt;&lt;/td&gt;&lt;td width="9%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;DKK'000&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;&lt;b&gt;Provision for returned goods&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Provision for returned goods 1 December&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;142&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;807&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Used during the year&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;-654&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;-1.998&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Provision for the year&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;3.120&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;1.333&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;&lt;b&gt;Provision for returned goods 30 November&lt;/b&gt;&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;&lt;b&gt;2.609&lt;/b&gt;&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;&lt;b&gt;142&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;The provisions comprise of anticipated costs relating to returned goods. The Company expects to use the provision over the next year.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;&lt;b&gt;Provision for restructuring&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Provision for restructuring 1 December&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;0&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;2.267&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Used during the year&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;0&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;-10.156&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Provision for the year&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;814&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;7.889&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;&lt;b&gt;Provisionfor restructuring 30 November&lt;/b&gt;&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;&lt;b&gt;814&lt;/b&gt;&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;&lt;b&gt;0&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;&lt;b&gt;Total provisions 30 November&lt;/b&gt;&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;&lt;b&gt;3.423&lt;/b&gt;&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;&lt;b&gt;142&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DisclosureOfOtherProvisions>
  <fsa:DisclosureOfOtherPayables contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;&lt;b&gt;Other payables&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" &gt;&lt;/td&gt;&lt;td width="5%" &gt;&lt;/td&gt;&lt;td width="19%" &gt;&lt;/td&gt;&lt;td width="6%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;2020/21&lt;/b&gt;&lt;/td&gt;&lt;td width="9%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;2019/20&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" &gt;&lt;/td&gt;&lt;td width="5%" &gt;&lt;/td&gt;&lt;td width="19%" &gt;&lt;/td&gt;&lt;td width="6%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;DKK'000&lt;/b&gt;&lt;/td&gt;&lt;td width="9%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;DKK'000&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;VAT and taxes&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;29.018&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;1.932&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Payable wages and salaries inclusive holiday provision&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;26.432&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;30.757&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Other payables&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;14.419&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;18.021&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="61%" &gt;&lt;/td&gt;&lt;td width="5%" &gt;&lt;/td&gt;&lt;td width="19%" &gt;&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;69.869&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;50.710&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DisclosureOfOtherPayables>
  <fsa:DisclosureOfContingentLiabilities contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td width="100%" colspan="1" align="left" valign="middle" &gt;&lt;b&gt;Contingent liabilities and other financial obligations&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="1" align="left" valign="middle" &gt;&lt;b&gt;Lease obligations&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="1" align="left" valign="middle" &gt;The Company has entered into operating leases regarding cars and other operating equipment. The remaining payments for lease obligations amount to DKK 7,3 million (2019/20 figure of DKK 7,6 million).&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="1" align="left" valign="middle" &gt;On December 14 2012, the Company entered into a commercial lease agreement with Wihlborgs A/S to rent 39.11% of the total gross surface area (4,544 of 11,620 m2) of the building located in Lautrupvang 8, Ballerup, previously owned by the Company. As per 01.11.2020, the Company changed the lease agreement with Wihlborgs A/S to reduce the area of basement. Therefore, the Company now rent 36.45% of the total gross surface area (4,236 of 11,620 m2) of the building. The cost of the annual rent excluding VAT is DKK 3,456,662,23. This amount is payable in four quarterly installments due 1st January, 1st April, 1st June and 1st October. Both parties may terminate the lease including roof terrace area and parking places by giving six months’ prior written notice to expire on the last day of a month.The landlord may terminate the lease including roof terrace area and parking places – except in the event of breach – to expire no earlier than 1 September 2032.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DisclosureOfContingentLiabilities>
  <fsa:DisclosureOfRelatedParties contextRef="ctx1" xml:lang="da">&lt;table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse"  width="100%"&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;&lt;b&gt;Related party disclosures&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;&lt;b&gt;Pfizer ApS' related parties comprise the following&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;&lt;b&gt;Description&lt;/b&gt;&lt;/td&gt;&lt;td width="6%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;2020/21&lt;/b&gt;&lt;/td&gt;&lt;td width="9%" colspan="1" align="right" valign="middle" &gt;&lt;b&gt;2019/20&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Provision of Above Market services by Pfizer ApS to Pfizer Worldwide Services&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;76.056&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;62.658&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Provisionof clinical trial support services by Pfizer ApS to Pfizer Inc.&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;12.132&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;10.927&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Provision of co-promote services by Pfizer Aps to Pfizer Worldwide Services&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;15.707&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;17.298&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Receipt of services by Pfizer ApS from Pfizer PFE ApS - domestic transation&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;0&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;252&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Provision of services by Pfizer ApS to - Pfizer PFE ApS - domestic transaction&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;0&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;5.861&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Provision of services by Pfizer ApS to - UEBV Netherlands&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;0&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;9&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Purchase of finished goods by Pfizer ApS from various Pfizer suppliers&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;1.207.543&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;281.126&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Sales of finished goods by Pfizer ApS to Pfizer affiliates&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;5.207&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;25.544&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="85%" colspan="3" align="left" valign="middle" &gt;Net of receipt/provision of management services by Pfizer ApS to/ from Pfizer Norge AS and Pfizer AS in Norway&lt;/td&gt;&lt;td width="6%" align="right" valign="middle" &gt;1.490&lt;/td&gt;&lt;td width="9%" align="right" valign="middle" &gt;1.426&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;Receivables and payables to group enterprises are disclosed in the balance sheet.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;&lt;b&gt;Control&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;Pfizer ApS is owned 100% by Pfizer Health AB, Vetenskapsvägen 10, 191 90 Sollentuna, Sverige.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;Furthermore, the Company is included in the consolidated financial statements of the ultimate parent company Pfizer Inc., 219-8-6A East 42nd Street, New York, N.Y. 10017, USA.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="100%" colspan="5" align="left" valign="middle" &gt;The consolidated financial statements of Pfizer Inc are available at the Company’s address or on the Company’s website at: https://annualreview.pfizer.com&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fsa:DisclosureOfRelatedParties>
  <gsd:InformationOnTypeOfSubmittedReport contextRef="ctx1">Årsrapport</gsd:InformationOnTypeOfSubmittedReport>
  <gsd:IdentificationNumberCvrOfSubmittingEnterprise contextRef="ctx1">33771231</gsd:IdentificationNumberCvrOfSubmittingEnterprise>
  <gsd:NameOfSubmittingEnterprise contextRef="ctx1" xml:lang="da">PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab</gsd:NameOfSubmittingEnterprise>
  <gsd:AddressOfSubmittingEnterpriseStreetAndNumber contextRef="ctx1" xml:lang="da">Strandvejen  44</gsd:AddressOfSubmittingEnterpriseStreetAndNumber>
  <gsd:AddressOfSubmittingEnterprisePostcodeAndTown contextRef="ctx1" xml:lang="da">2900 Hellerup</gsd:AddressOfSubmittingEnterprisePostcodeAndTown>
  <gsd:ToolForPreparingTheXBRLInstanceDocument contextRef="ctx1" xml:lang="da">xWizard version 1.1.1121.0, by EasyX Aps. www.easyx.eu</gsd:ToolForPreparingTheXBRLInstanceDocument>
  <gsd:PrecedingReportingPeriodStartDate contextRef="ctx1">2019-12-01</gsd:PrecedingReportingPeriodStartDate>
  <gsd:PredingReportingPeriodEndDate contextRef="ctx1">2020-11-30</gsd:PredingReportingPeriodEndDate>
  <cmn:TypeOfAuditorAssistance contextRef="ctx1">Revisionspåtegning</cmn:TypeOfAuditorAssistance>
  <arr:TypeOfBasisForModifiedOpinionOnAuditedFinancialStatements contextRef="ctx1">Grundlag for konklusion</arr:TypeOfBasisForModifiedOpinionOnAuditedFinancialStatements>
  <arr:TypeOfModifiedOpinionOnAuditedFinancialStatements contextRef="ctx1">Konklusion</arr:TypeOfModifiedOpinionOnAuditedFinancialStatements>
  <cmn:NameAndSurnameOfMemberOfExecutiveBoard contextRef="ctx2" xml:lang="da">Lars Møller</cmn:NameAndSurnameOfMemberOfExecutiveBoard>
  <cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx3" xml:lang="da">Adam Preben Guhle</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
  <cmn:TitleOfMemberOfSupervisoryBoard contextRef="ctx3" xml:lang="da">Chairman</cmn:TitleOfMemberOfSupervisoryBoard>
  <cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx4" xml:lang="da">Lars Møller</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
  <cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx5" xml:lang="da">Anne Bloch Thomsen</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
  <fsa:Revenue contextRef="ctx6" unitRef="vDKK" decimals="-3">319940000</fsa:Revenue>
  <fsa:ProfitLossFromOrdinaryOperatingActivities contextRef="ctx6" unitRef="vDKK" decimals="-3">24343000</fsa:ProfitLossFromOrdinaryOperatingActivities>
  <fsa:ResultsFromNetFinancials contextRef="ctx6" unitRef="vDKK" decimals="-3">-100000</fsa:ResultsFromNetFinancials>
  <fsa:ProfitLoss contextRef="ctx6" unitRef="vDKK" decimals="-3">29031000</fsa:ProfitLoss>
  <mrv:OperatingMargin contextRef="ctx6" unitRef="pure" decimals="3">0.076</mrv:OperatingMargin>
  <mrv:ReturnOnInvestedCapital contextRef="ctx6" unitRef="pure" decimals="3">0.062</mrv:ReturnOnInvestedCapital>
  <mrv:EquityRatio contextRef="ctx6" unitRef="pure" decimals="3">0.695</mrv:EquityRatio>
  <fsa:AverageNumberOfEmployees contextRef="ctx6" unitRef="pure" decimals="0">107</fsa:AverageNumberOfEmployees>
  <fsa:Revenue contextRef="ctx7" unitRef="vDKK" decimals="-3">421709000</fsa:Revenue>
  <fsa:ProfitLossFromOrdinaryOperatingActivities contextRef="ctx7" unitRef="vDKK" decimals="-3">30008000</fsa:ProfitLossFromOrdinaryOperatingActivities>
  <fsa:ResultsFromNetFinancials contextRef="ctx7" unitRef="vDKK" decimals="-3">-106000</fsa:ResultsFromNetFinancials>
  <fsa:ProfitLoss contextRef="ctx7" unitRef="vDKK" decimals="-3">18996000</fsa:ProfitLoss>
  <mrv:OperatingMargin contextRef="ctx7" unitRef="pure" decimals="3">0.071</mrv:OperatingMargin>
  <mrv:ReturnOnInvestedCapital contextRef="ctx7" unitRef="pure" decimals="3">0.071</mrv:ReturnOnInvestedCapital>
  <mrv:EquityRatio contextRef="ctx7" unitRef="pure" decimals="3">0.644</mrv:EquityRatio>
  <fsa:AverageNumberOfEmployees contextRef="ctx7" unitRef="pure" decimals="0">136</fsa:AverageNumberOfEmployees>
  <fsa:Revenue contextRef="ctx8" unitRef="vDKK" decimals="-3">459733000</fsa:Revenue>
  <fsa:ProfitLossFromOrdinaryOperatingActivities contextRef="ctx8" unitRef="vDKK" decimals="-3">30813000</fsa:ProfitLossFromOrdinaryOperatingActivities>
  <fsa:ResultsFromNetFinancials contextRef="ctx8" unitRef="vDKK" decimals="-3">38000</fsa:ResultsFromNetFinancials>
  <fsa:ProfitLoss contextRef="ctx8" unitRef="vDKK" decimals="-3">21841000</fsa:ProfitLoss>
  <mrv:OperatingMargin contextRef="ctx8" unitRef="pure" decimals="3">0.067</mrv:OperatingMargin>
  <mrv:ReturnOnInvestedCapital contextRef="ctx8" unitRef="pure" decimals="3">0.076</mrv:ReturnOnInvestedCapital>
  <mrv:EquityRatio contextRef="ctx8" unitRef="pure" decimals="3">0.683</mrv:EquityRatio>
  <fsa:AverageNumberOfEmployees contextRef="ctx8" unitRef="pure" decimals="0">137</fsa:AverageNumberOfEmployees>
  <fsa:Revenue contextRef="ctx9" unitRef="vDKK" decimals="-3">387024000</fsa:Revenue>
  <fsa:ProfitLossFromOrdinaryOperatingActivities contextRef="ctx9" unitRef="vDKK" decimals="-3">23032000</fsa:ProfitLossFromOrdinaryOperatingActivities>
  <fsa:ResultsFromNetFinancials contextRef="ctx9" unitRef="vDKK" decimals="-3">35000</fsa:ResultsFromNetFinancials>
  <fsa:ProfitLoss contextRef="ctx9" unitRef="vDKK" decimals="-3">17982000</fsa:ProfitLoss>
  <mrv:OperatingMargin contextRef="ctx9" unitRef="pure" decimals="2">0.06</mrv:OperatingMargin>
  <mrv:ReturnOnInvestedCapital contextRef="ctx9" unitRef="pure" decimals="2">0.06</mrv:ReturnOnInvestedCapital>
  <mrv:EquityRatio contextRef="ctx9" unitRef="pure" decimals="3">0.756</mrv:EquityRatio>
  <fsa:AverageNumberOfEmployees contextRef="ctx9" unitRef="pure" decimals="0">145</fsa:AverageNumberOfEmployees>
  <mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx10" xml:lang="da">Fixed assets</mrv:NameOfKeyFigureOrFinancialRatio>
  <mrv:ValueOfKeyFigureOrFinancialRatioMonetary contextRef="ctx10" unitRef="vDKK" decimals="-3">379000</mrv:ValueOfKeyFigureOrFinancialRatioMonetary>
  <mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx11" xml:lang="da">Fixed assets</mrv:NameOfKeyFigureOrFinancialRatio>
  <mrv:ValueOfKeyFigureOrFinancialRatioMonetary contextRef="ctx11" unitRef="vDKK" decimals="-3">466000</mrv:ValueOfKeyFigureOrFinancialRatioMonetary>
  <mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx12" xml:lang="da">Fixed assets</mrv:NameOfKeyFigureOrFinancialRatio>
  <mrv:ValueOfKeyFigureOrFinancialRatioMonetary contextRef="ctx12" unitRef="vDKK" decimals="-3">988000</mrv:ValueOfKeyFigureOrFinancialRatioMonetary>
  <mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx13" xml:lang="da">Fixed assets</mrv:NameOfKeyFigureOrFinancialRatio>
  <mrv:ValueOfKeyFigureOrFinancialRatioMonetary contextRef="ctx13" unitRef="vDKK" decimals="-3">1609000</mrv:ValueOfKeyFigureOrFinancialRatioMonetary>
  <mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx14" xml:lang="da">Fixed assets</mrv:NameOfKeyFigureOrFinancialRatio>
  <mrv:ValueOfKeyFigureOrFinancialRatioMonetary contextRef="ctx14" unitRef="vDKK" decimals="-3">3355000</mrv:ValueOfKeyFigureOrFinancialRatioMonetary>
  <mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx15" xml:lang="da">Current assets</mrv:NameOfKeyFigureOrFinancialRatio>
  <mrv:ValueOfKeyFigureOrFinancialRatioMonetary contextRef="ctx15" unitRef="vDKK" decimals="-3">783324000</mrv:ValueOfKeyFigureOrFinancialRatioMonetary>
  <mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx16" xml:lang="da">Current assets</mrv:NameOfKeyFigureOrFinancialRatio>
  <mrv:ValueOfKeyFigureOrFinancialRatioMonetary contextRef="ctx16" unitRef="vDKK" decimals="-3">434247000</mrv:ValueOfKeyFigureOrFinancialRatioMonetary>
  <mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx17" xml:lang="da">Current assets</mrv:NameOfKeyFigureOrFinancialRatio>
  <mrv:ValueOfKeyFigureOrFinancialRatioMonetary contextRef="ctx17" unitRef="vDKK" decimals="-3">687360000</mrv:ValueOfKeyFigureOrFinancialRatioMonetary>
  <mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx18" xml:lang="da">Current assets</mrv:NameOfKeyFigureOrFinancialRatio>
  <mrv:ValueOfKeyFigureOrFinancialRatioMonetary contextRef="ctx18" unitRef="vDKK" decimals="-3">619438000</mrv:ValueOfKeyFigureOrFinancialRatioMonetary>
  <mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx19" xml:lang="da">Current assets</mrv:NameOfKeyFigureOrFinancialRatio>
  <mrv:ValueOfKeyFigureOrFinancialRatioMonetary contextRef="ctx19" unitRef="vDKK" decimals="-3">528579000</mrv:ValueOfKeyFigureOrFinancialRatioMonetary>
  <fsa:Assets contextRef="ctx20" unitRef="vDKK" decimals="-3">783703000</fsa:Assets>
  <fsa:Equity contextRef="ctx20" unitRef="vDKK" decimals="-3">483044000</fsa:Equity>
  <fsa:FixturesFittingsToolsAndEquipment contextRef="ctx20" unitRef="vDKK" decimals="-3">379000</fsa:FixturesFittingsToolsAndEquipment>
  <fsa:NoncurrentAssets contextRef="ctx20" unitRef="vDKK" decimals="-3">379000</fsa:NoncurrentAssets>
  <fsa:Inventories contextRef="ctx20" unitRef="vDKK" decimals="-3">143350000</fsa:Inventories>
  <fsa:ShorttermTradeReceivables contextRef="ctx20" unitRef="vDKK" decimals="-3">156843000</fsa:ShorttermTradeReceivables>
  <fsa:ShorttermReceivablesFromGroupEnterprises contextRef="ctx20" unitRef="vDKK" decimals="-3">432832000</fsa:ShorttermReceivablesFromGroupEnterprises>
  <fsa:OtherShorttermReceivables contextRef="ctx20" unitRef="vDKK" decimals="-3">552000</fsa:OtherShorttermReceivables>
  <fsa:DeferredIncomeAssets contextRef="ctx20" unitRef="vDKK" decimals="-3">1981000</fsa:DeferredIncomeAssets>
  <fsa:ShorttermTaxReceivables contextRef="ctx20" unitRef="vDKK" decimals="-3">31890000</fsa:ShorttermTaxReceivables>
  <fsa:CurrentDeferredTaxAssets contextRef="ctx20" unitRef="vDKK" decimals="-3">3474000</fsa:CurrentDeferredTaxAssets>
  <fsa:CashAndCashEquivalents contextRef="ctx20" unitRef="vDKK" decimals="-3">12402000</fsa:CashAndCashEquivalents>
  <fsa:AssetsMeantForSale contextRef="ctx20" unitRef="vDKK" decimals="-3">0</fsa:AssetsMeantForSale>
  <fsa:CurrentAssets contextRef="ctx20" unitRef="vDKK" decimals="-3">783324000</fsa:CurrentAssets>
  <fsa:ContributedCapital contextRef="ctx20" unitRef="vDKK" decimals="-3">250772000</fsa:ContributedCapital>
  <fsa:RetainedEarnings contextRef="ctx20" unitRef="vDKK" decimals="-3">232272000</fsa:RetainedEarnings>
  <fsa:ProposedDividendRecognisedInEquity contextRef="ctx20" unitRef="vDKK" decimals="-3">0</fsa:ProposedDividendRecognisedInEquity>
  <fsa:OtherProvisions contextRef="ctx20" unitRef="vDKK" decimals="-3">3423000</fsa:OtherProvisions>
  <fsa:Provisions contextRef="ctx20" unitRef="vDKK" decimals="-3">3423000</fsa:Provisions>
  <fsa:ShorttermTradePayables contextRef="ctx20" unitRef="vDKK" decimals="-3">17630000</fsa:ShorttermTradePayables>
  <fsa:ShorttermPayablesToGroupEnterprises contextRef="ctx20" unitRef="vDKK" decimals="-3">209738000</fsa:ShorttermPayablesToGroupEnterprises>
  <fsa:ShorttermTaxPayables contextRef="ctx20" unitRef="vDKK" decimals="-3">0</fsa:ShorttermTaxPayables>
  <fsa:OtherShorttermPayables contextRef="ctx20" unitRef="vDKK" decimals="-3">69868000</fsa:OtherShorttermPayables>
  <fsa:LiabilitiesOtherThanProvisions contextRef="ctx20" unitRef="vDKK" decimals="-3">297236000</fsa:LiabilitiesOtherThanProvisions>
  <fsa:LiabilitiesRelatedToAssetsMeantForSale contextRef="ctx20" unitRef="vDKK" decimals="-3">0</fsa:LiabilitiesRelatedToAssetsMeantForSale>
  <fsa:LiabilitiesAndEquity contextRef="ctx20" unitRef="vDKK" decimals="-3">783703000</fsa:LiabilitiesAndEquity>
  <fsa:Assets contextRef="ctx21" unitRef="vDKK" decimals="-3">434713000</fsa:Assets>
  <fsa:Equity contextRef="ctx21" unitRef="vDKK" decimals="-3">302210000</fsa:Equity>
  <fsa:Assets contextRef="ctx22" unitRef="vDKK" decimals="-3">688348000</fsa:Assets>
  <fsa:Equity contextRef="ctx22" unitRef="vDKK" decimals="-3">443179000</fsa:Equity>
  <fsa:Assets contextRef="ctx23" unitRef="vDKK" decimals="-3">621047000</fsa:Assets>
  <fsa:Equity contextRef="ctx23" unitRef="vDKK" decimals="-3">424183000</fsa:Equity>
  <fsa:Assets contextRef="ctx24" unitRef="vDKK" decimals="-3">531934000</fsa:Assets>
  <fsa:Equity contextRef="ctx24" unitRef="vDKK" decimals="-3">402342000</fsa:Equity>
  <mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx25" xml:lang="da">Provisions</mrv:NameOfKeyFigureOrFinancialRatio>
  <mrv:ValueOfKeyFigureOrFinancialRatioMonetary contextRef="ctx25" unitRef="vDKK" decimals="-3">3423000</mrv:ValueOfKeyFigureOrFinancialRatioMonetary>
  <mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx26" xml:lang="da">Provisions</mrv:NameOfKeyFigureOrFinancialRatio>
  <mrv:ValueOfKeyFigureOrFinancialRatioMonetary contextRef="ctx26" unitRef="vDKK" decimals="-3">142000</mrv:ValueOfKeyFigureOrFinancialRatioMonetary>
  <mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx27" xml:lang="da">Provisions</mrv:NameOfKeyFigureOrFinancialRatio>
  <mrv:ValueOfKeyFigureOrFinancialRatioMonetary contextRef="ctx27" unitRef="vDKK" decimals="-3">3074000</mrv:ValueOfKeyFigureOrFinancialRatioMonetary>
  <mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx28" xml:lang="da">Provisions</mrv:NameOfKeyFigureOrFinancialRatio>
  <mrv:ValueOfKeyFigureOrFinancialRatioMonetary contextRef="ctx28" unitRef="vDKK" decimals="-3">10144000</mrv:ValueOfKeyFigureOrFinancialRatioMonetary>
  <mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx29" xml:lang="da">Provisions</mrv:NameOfKeyFigureOrFinancialRatio>
  <mrv:ValueOfKeyFigureOrFinancialRatioMonetary contextRef="ctx29" unitRef="vDKK" decimals="-3">10061000</mrv:ValueOfKeyFigureOrFinancialRatioMonetary>
  <mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx30" xml:lang="da">Short-term liabilities other than provisions</mrv:NameOfKeyFigureOrFinancialRatio>
  <mrv:ValueOfKeyFigureOrFinancialRatioMonetary contextRef="ctx30" unitRef="vDKK" decimals="-3">297236000</mrv:ValueOfKeyFigureOrFinancialRatioMonetary>
  <mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx31" xml:lang="da">Short-term liabilities other than provisions</mrv:NameOfKeyFigureOrFinancialRatio>
  <mrv:ValueOfKeyFigureOrFinancialRatioMonetary contextRef="ctx31" unitRef="vDKK" decimals="-3">130289000</mrv:ValueOfKeyFigureOrFinancialRatioMonetary>
  <mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx32" xml:lang="da">Short-term liabilities other than provisions</mrv:NameOfKeyFigureOrFinancialRatio>
  <mrv:ValueOfKeyFigureOrFinancialRatioMonetary contextRef="ctx32" unitRef="vDKK" decimals="-3">242095000</mrv:ValueOfKeyFigureOrFinancialRatioMonetary>
  <mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx33" xml:lang="da">Short-term liabilities other than provisions</mrv:NameOfKeyFigureOrFinancialRatio>
  <mrv:ValueOfKeyFigureOrFinancialRatioMonetary contextRef="ctx33" unitRef="vDKK" decimals="-3">186720000</mrv:ValueOfKeyFigureOrFinancialRatioMonetary>
  <mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx34" xml:lang="da">Short-term liabilities other than provisions</mrv:NameOfKeyFigureOrFinancialRatio>
  <mrv:ValueOfKeyFigureOrFinancialRatioMonetary contextRef="ctx34" unitRef="vDKK" decimals="-3">119531000</mrv:ValueOfKeyFigureOrFinancialRatioMonetary>
  <mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx35" xml:lang="da">Current ratio</mrv:NameOfKeyFigureOrFinancialRatio>
  <mrv:ValueOfKeyFigureOrFinancialRatio contextRef="ctx35" unitRef="pure" decimals="3">2.635</mrv:ValueOfKeyFigureOrFinancialRatio>
  <mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx36" xml:lang="da">Current ratio</mrv:NameOfKeyFigureOrFinancialRatio>
  <mrv:ValueOfKeyFigureOrFinancialRatio contextRef="ctx36" unitRef="pure" decimals="3">3.333</mrv:ValueOfKeyFigureOrFinancialRatio>
  <mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx37" xml:lang="da">Current ratio</mrv:NameOfKeyFigureOrFinancialRatio>
  <mrv:ValueOfKeyFigureOrFinancialRatio contextRef="ctx37" unitRef="pure" decimals="3">2.839</mrv:ValueOfKeyFigureOrFinancialRatio>
  <mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx38" xml:lang="da">Current ratio</mrv:NameOfKeyFigureOrFinancialRatio>
  <mrv:ValueOfKeyFigureOrFinancialRatio contextRef="ctx38" unitRef="pure" decimals="3">3.317</mrv:ValueOfKeyFigureOrFinancialRatio>
  <mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx39" xml:lang="da">Current ratio</mrv:NameOfKeyFigureOrFinancialRatio>
  <mrv:ValueOfKeyFigureOrFinancialRatio contextRef="ctx39" unitRef="pure" decimals="3">4.422</mrv:ValueOfKeyFigureOrFinancialRatio>
  <mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx40" xml:lang="da">Return on average equity</mrv:NameOfKeyFigureOrFinancialRatio>
  <mrv:ValueOfKeyFigureOrFinancialRatio contextRef="ctx40" unitRef="pure" decimals="3">0.076</mrv:ValueOfKeyFigureOrFinancialRatio>
  <mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx41" xml:lang="da">Return on average equity</mrv:NameOfKeyFigureOrFinancialRatio>
  <mrv:ValueOfKeyFigureOrFinancialRatio contextRef="ctx41" unitRef="pure" decimals="3">0.076</mrv:ValueOfKeyFigureOrFinancialRatio>
  <mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx42" xml:lang="da">Return on average equity</mrv:NameOfKeyFigureOrFinancialRatio>
  <mrv:ValueOfKeyFigureOrFinancialRatio contextRef="ctx42" unitRef="pure" decimals="3">0.044</mrv:ValueOfKeyFigureOrFinancialRatio>
  <mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx43" xml:lang="da">Return on average equity</mrv:NameOfKeyFigureOrFinancialRatio>
  <mrv:ValueOfKeyFigureOrFinancialRatio contextRef="ctx43" unitRef="pure" decimals="3">0.054</mrv:ValueOfKeyFigureOrFinancialRatio>
  <mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx44" xml:lang="da">Return on average equity</mrv:NameOfKeyFigureOrFinancialRatio>
  <mrv:ValueOfKeyFigureOrFinancialRatio contextRef="ctx44" unitRef="pure" decimals="3">0.047</mrv:ValueOfKeyFigureOrFinancialRatio>
  <fsa:Revenue contextRef="ctx45" unitRef="vDKK" decimals="-3">319940000</fsa:Revenue>
  <fsa:CostOfSales contextRef="ctx45" unitRef="vDKK" decimals="-3">194852000</fsa:CostOfSales>
  <fsa:GrossResult contextRef="ctx45" unitRef="vDKK" decimals="-3">125088000</fsa:GrossResult>
  <fsa:DistributionCosts contextRef="ctx45" unitRef="vDKK" decimals="-3">106100000</fsa:DistributionCosts>
  <fsa:DevelopmentExpenditure contextRef="ctx45" unitRef="vDKK" decimals="-3">60251000</fsa:DevelopmentExpenditure>
  <fsa:AdministrativeExpenses contextRef="ctx45" unitRef="vDKK" decimals="-3">32247000</fsa:AdministrativeExpenses>
  <fsa:OtherOperatingIncome contextRef="ctx45" unitRef="vDKK" decimals="-3">97853000</fsa:OtherOperatingIncome>
  <fsa:ProfitLossFromOrdinaryOperatingActivities contextRef="ctx45" unitRef="vDKK" decimals="-3">24343000</fsa:ProfitLossFromOrdinaryOperatingActivities>
  <fsa:OtherFinanceIncome contextRef="ctx45" unitRef="vDKK" decimals="-3">-100000</fsa:OtherFinanceIncome>
  <fsa:ProfitLossFromOrdinaryActivitiesBeforeTax contextRef="ctx45" unitRef="vDKK" decimals="-3">24243000</fsa:ProfitLossFromOrdinaryActivitiesBeforeTax>
  <fsa:TaxExpense contextRef="ctx45" unitRef="vDKK" decimals="-3">2560000</fsa:TaxExpense>
  <fsa:ProfitLossFromContinuingOperations contextRef="ctx45" unitRef="vDKK" decimals="-3">21683000</fsa:ProfitLossFromContinuingOperations>
  <fsa:ProfitLossFromDiscontinuedOperations contextRef="ctx45" unitRef="vDKK" decimals="-3">7348000</fsa:ProfitLossFromDiscontinuedOperations>
  <fsa:ProfitLoss contextRef="ctx45" unitRef="vDKK" decimals="-3">29031000</fsa:ProfitLoss>
  <fsa:AverageNumberOfEmployees contextRef="ctx45" unitRef="pure" decimals="0">107</fsa:AverageNumberOfEmployees>
  <fsa:FixturesFittingsToolsAndEquipment contextRef="ctx46" unitRef="vDKK" decimals="-3">466000</fsa:FixturesFittingsToolsAndEquipment>
  <fsa:NoncurrentAssets contextRef="ctx46" unitRef="vDKK" decimals="-3">466000</fsa:NoncurrentAssets>
  <fsa:Inventories contextRef="ctx46" unitRef="vDKK" decimals="-3">204415000</fsa:Inventories>
  <fsa:ShorttermTradeReceivables contextRef="ctx46" unitRef="vDKK" decimals="-3">36242000</fsa:ShorttermTradeReceivables>
  <fsa:ShorttermReceivablesFromGroupEnterprises contextRef="ctx46" unitRef="vDKK" decimals="-3">174241000</fsa:ShorttermReceivablesFromGroupEnterprises>
  <fsa:OtherShorttermReceivables contextRef="ctx46" unitRef="vDKK" decimals="-3">786000</fsa:OtherShorttermReceivables>
  <fsa:DeferredIncomeAssets contextRef="ctx46" unitRef="vDKK" decimals="-3">1045000</fsa:DeferredIncomeAssets>
  <fsa:ShorttermTaxReceivables contextRef="ctx46" unitRef="vDKK" decimals="-3">5921000</fsa:ShorttermTaxReceivables>
  <fsa:CurrentDeferredTaxAssets contextRef="ctx46" unitRef="vDKK" decimals="-3">2780000</fsa:CurrentDeferredTaxAssets>
  <fsa:CashAndCashEquivalents contextRef="ctx46" unitRef="vDKK" decimals="-3">861000</fsa:CashAndCashEquivalents>
  <fsa:AssetsMeantForSale contextRef="ctx46" unitRef="vDKK" decimals="-3">7956000</fsa:AssetsMeantForSale>
  <fsa:CurrentAssets contextRef="ctx46" unitRef="vDKK" decimals="-3">434247000</fsa:CurrentAssets>
  <fsa:Assets contextRef="ctx46" unitRef="vDKK" decimals="-3">434713000</fsa:Assets>
  <fsa:ContributedCapital contextRef="ctx46" unitRef="vDKK" decimals="-3">250771000</fsa:ContributedCapital>
  <fsa:RetainedEarnings contextRef="ctx46" unitRef="vDKK" decimals="-3">51439000</fsa:RetainedEarnings>
  <fsa:ProposedDividendRecognisedInEquity contextRef="ctx46" unitRef="vDKK" decimals="-3">0</fsa:ProposedDividendRecognisedInEquity>
  <fsa:Equity contextRef="ctx46" unitRef="vDKK" decimals="-3">302210000</fsa:Equity>
  <fsa:OtherProvisions contextRef="ctx46" unitRef="vDKK" decimals="-3">142000</fsa:OtherProvisions>
  <fsa:Provisions contextRef="ctx46" unitRef="vDKK" decimals="-3">142000</fsa:Provisions>
  <fsa:ShorttermTradePayables contextRef="ctx46" unitRef="vDKK" decimals="-3">21533000</fsa:ShorttermTradePayables>
  <fsa:ShorttermPayablesToGroupEnterprises contextRef="ctx46" unitRef="vDKK" decimals="-3">58046000</fsa:ShorttermPayablesToGroupEnterprises>
  <fsa:ShorttermTaxPayables contextRef="ctx46" unitRef="vDKK" decimals="-3">0</fsa:ShorttermTaxPayables>
  <fsa:OtherShorttermPayables contextRef="ctx46" unitRef="vDKK" decimals="-3">50710000</fsa:OtherShorttermPayables>
  <fsa:LiabilitiesOtherThanProvisions contextRef="ctx46" unitRef="vDKK" decimals="-3">130289000</fsa:LiabilitiesOtherThanProvisions>
  <fsa:LiabilitiesRelatedToAssetsMeantForSale contextRef="ctx46" unitRef="vDKK" decimals="-3">2072000</fsa:LiabilitiesRelatedToAssetsMeantForSale>
  <fsa:LiabilitiesAndEquity contextRef="ctx46" unitRef="vDKK" decimals="-3">434713000</fsa:LiabilitiesAndEquity>
  <fsa:ProfitLoss contextRef="ctx47" unitRef="vDKK" decimals="-3">232272000</fsa:ProfitLoss>
  <fsa:ProfitLoss contextRef="ctx48" unitRef="vDKK" decimals="-3">51439000</fsa:ProfitLoss>
  <gsd:AddressOfAuditorStreetName contextRef="ctx49" xml:lang="da">Dampfærgevej</gsd:AddressOfAuditorStreetName>
  <gsd:AddressOfAuditorPostCodeIdentifier contextRef="ctx49" xml:lang="da">DK-2100</gsd:AddressOfAuditorPostCodeIdentifier>
  <gsd:AddressOfAuditorStreetBuildingIdentifier contextRef="ctx49" xml:lang="da">28</gsd:AddressOfAuditorStreetBuildingIdentifier>
  <gsd:AddressOfAuditorDistrictName contextRef="ctx49" xml:lang="da">Copenhagen</gsd:AddressOfAuditorDistrictName>
  <cmn:NameOfAuditFirm contextRef="ctx49" xml:lang="da">KPMG Statsautoriseret Revisionspartnerselskab</cmn:NameOfAuditFirm>
  <cmn:IdentificationNumberCvrOfAuditFirm contextRef="ctx49">25578198</cmn:IdentificationNumberCvrOfAuditFirm>
  <cmn:NameAndSurnameOfAuditor contextRef="ctx49" xml:lang="da">Lau Bent Baun</cmn:NameAndSurnameOfAuditor>
  <cmn:DescriptionOfAuditor contextRef="ctx49" xml:lang="da">State Authorised Public Accountant</cmn:DescriptionOfAuditor>
  <cmn:IdentificationNumberOfAuditor contextRef="ctx49">mne26708</cmn:IdentificationNumberOfAuditor>
</xbrli:xbrl>